Dr. Carleton’s lifelong goal is to make medication use more effective and safer for all patients, particularly children. His current focus in meeting this goal is the use of patients’ genetic information to identify who is likely to suffer serious or permanently disabling reactions to specific drugs.
A key element of Dr. Carleton’s research is the communication of results to clinicians, patients, healthcare administrators, and government officials – those who also hold responsibilities to improve patient care within our systems of healthcare delivery.
Dr. Carleton has served in several past roles in both provincial and national agencies. He worked for many years with the BC PharmaCare division on drug policy programs, culminating as Lead, Drugs and Drug Policy for the BC Ministry of Health from 2005-06. He is the longest-serving member of the Canadian Agency for Drugs and Technologies in Health Expert Advisory Committee, having served in this capacity since the agency’s founding in 2003. Dr. Carleton was recently asked to serve the US Government as a Special Government Employee to advise the Advisory Committee for Pharmaceuticals and Clinical Pharmacology of the FDA on pediatric drug issues. He continues to advise and work with Health Canada on a number of initiatives to improve the safety of drugs for Canadians. Dr. Carleton is currently Chair of the BC Ministry of Health’s Data Stewardship Committee which advises the provincial government on health data issues and reviews data access applications for research and health planning purposes.
Dr. Carleton cares deeply for all the patients and families that he has the privilege to serve and is active in this capacity at both BC Children’s Hospital and the SunnyHill Health Centre for Children in Vancouver.